.

0 (hodnocen0 x )

EB

ONLINE

Cham : Springer International Publishing AG, 2020

1 online resource (138 pages)

ISBN 9783030477011 (electronic bk.)

ISBN 9783030477004

Print version: Treglia, Giorgio Evidence-Based Positron Emission Tomography Cham : Springer International Publishing AG,c2020 ISBN 9783030477004

Intro -- Preface -- Contents -- Part I: Introduction -- 1: Introduction to Different PET Radiopharmaceuticals and Hybrid Modalities (PET/CT and PET/MRI) -- 1.1 Physical Principles of Positron Emission Tomography and Hybrid Modalities -- 1.2 Hybrid Scanners: PET/CT and PET/MRI -- 1.3 Positron Emission Tomography Radiopharmaceuticals -- References -- 2: A Practical Guideline on Diagnostic and Prognostic Meta-Analyses -- 2.1 Introduction -- 2.2 A Clear Topic for Systematic Review: Formulating the Question -- 2.3 Which Articles Should Be Included? Search Strategy, Inclusion and Exclusion Criteria -- 2.4 Quality Assessment of the Included Studies -- 2.5 Data Extraction -- 2.6 Pooling Diagnostic Indices Across Studies and Reporting Heterogeneity -- 2.7 Discussion and Conclusion of Systematic Reviews -- 2.8 Final Comment -- References -- Part II: Evidence-Based PET in Oncology -- 3: Evidence-Based PET for Brain Tumours -- 3.1 Background -- 3.2 Evaluation of Suspicious Primary Brain Tumour -- 3.2.1 18F-FDG -- 3.2.2 11C-Methionine -- 3.2.3 18F-FET -- 3.2.4 18F-FDOPA -- 3.3 Glioma Grading -- 3.3.1 18F-FDG -- 3.3.2 11C-Methionine -- 3.3.3 18F-FET -- 3.3.4 18F-FDOPA -- 3.4 Delineation of Gliomas -- 3.5 Diagnosis of Recurrent Brain Tumours -- 3.5.1 18F-FDG -- 3.5.2 11C-Methionine -- 3.5.3 18F-FET -- 3.5.4 18F-FDOPA -- 3.5.5 18F-FLT -- 3.5.6 18C-Choline -- 3.6 Diagnosis of Brain Metastases -- 3.7 Diagnosis of Recurrent Brain Metastases -- 3.8 Diagnosis of Primary Central Nervous System Lymphoma (PCNSL) -- 3.9 Prognostic Value in Patients with Glioma -- 3.10 Conclusions -- References -- 4: Evidence-Based PET for Head and Neck Tumours -- 4.1 Introduction -- 4.2 Staging -- 4.2.1 T Staging -- 4.2.2 Nodal and Distant Metastases Detection -- 4.3 Prognostic Value -- 4.4 Post-treatment Evaluation.

11.2.2 Prognostic Value of Myocardial PET -- 11.3 Assessment of Myocardial Viability -- 11.4 Microvascular Disease -- 11.5 Cardiac Hybrid Imaging -- 11.6 Cardiac Amyloidosis -- References -- Part IV: Evidence-Based PET in Infection and Inflammation -- 12: Evidence-Based PET for Infectious and Inflammatory Diseases -- 12.1 Introduction -- 12.2 Fever of Unknown Origin (FUO) -- 12.3 Large Vessel Vasculitis (LVV) -- 12.4 Infectious Endocarditis and Cardiovascular Implantable Electronic Device Infections -- 12.5 Vascular Graft Infections -- 12.6 Sarcoidosis -- 12.7 Musculoskeletal Infections -- 12.8 Inflammatory Rheumatic Diseases -- 12.9 Inflammatory Bowel Diseases -- References -- Part V: Evidence-Based PET in Neurology -- 13: Evidence-Based PET for Neurological Diseases -- 13.1 Introduction -- 13.2 Evidence-Based PET in Neurodegenerative Dementia -- 13.3 Evidence-Based PET for Movement Disorders ---

5.5 Evidence-Based Data on PET in Esophageal Tumours -- 5.5.1 Staging -- 5.5.2 Restaging -- 5.5.3 Predictive and Prognostic Value -- References -- 6: Evidence-Based PET for Breast Cancer -- 6.1 Introduction -- 6.2 Staging -- 6.3 Restaging and Assessment of Response to Neoadjuvant Therapy -- 6.4 Prognostic Value -- 6.5 Incidental 18F-FDG Uptake -- 6.6 18F-FDG Positron Emission Mammography -- 6.7 PET/MRI -- 6.8 Other PET Tracers Beyond 18F-FDG -- References -- 7: Evidence-Based PET for Abdominal and Pelvic Tumours -- 7.1 Introduction -- 7.2 PET in Gastrointestinal Tumours -- 7.2.1 Colorectal Cancer -- 7.2.2 Gastric Cancer -- 7.2.3 Anal Cancer -- 7.2.4 Stromal Tumours (GIST) -- 7.2.5 Hepato-biliary Tumours -- 7.2.6 Liver Metastases -- 7.2.7 Pancreatic Cancer -- 7.3 PET in Gynaecological Tumours -- 7.3.1 Cervical Cancer -- 7.3.2 Endometrial Cancer -- 7.3.3 Ovarian Cancer -- 7.3.4 Peritoneal Carcinomatosis ---

8.5.3 Impact of PET in Patients with Paraneoplastic Syndromes -- References -- 9: Evidence-Based PET for Haematological Tumours -- 9.1 Introduction -- 9.2 18F-FDG PET or PET/CT in Staging or Detection -- 9.2.1 Post-transplant Lymphoproliferative Disorder -- 9.2.2 Follicular Lymphoma -- 9.2.3 Marginal Zone Lymphoma of the Mucosa-Associated Lymphoid Tissue -- 9.2.4 Bone Marrow Involvement in Lymphoma -- 9.2.5 Natural Killer/T-Cell Lymphoma -- 9.2.6 Multiple Myeloma -- 9.3 18F-FDG PET or PET/CT in Treatment Response Evaluation (Interim and/or End of Therapy) -- 9.3.1 Post-transplant Lymphoproliferative Disorder -- 9.3.2 Hodgkin and Non-Hodgkin Lymphomas -- 9.4 18F-FDG PET or PET/CT in Prognosis/Outcome Evaluation -- 9.4.1 Hodgkin and Non-Hodgkin Lymphomas -- 9.4.2 Multiple Myeloma -- 9.5 Prognostic Role of Semi-quantitative PET Parameters ---

10: Evidence-Based PET for Endocrine Tumours and Disorders -- 10.1 Introduction -- 10.2 Adrenal Tumours and Paragangliomas -- 10.2.1 Characterization of Adrenal Masses -- 10.2.2 Paragangliomas -- 10.3 Neuroblastoma -- 10.4 Merkel Cell Carcinoma -- 10.5 Gastroenteropancreatic and Pulmonary Neuroendocrine Tumours -- 10.6 Congenital Hyperinsulinism -- 10.7 Thyroid Diseases -- 10.7.1 Thyroid Incidentalomas -- 10.7.2 Indeterminate Thyroid Nodules -- 10.7.3 Recurrence of Differentiated Thyroid Cancer -- 10.7.4 Recurrence of Medullary Thyroid Cancer -- 10.8 Parathyroid Diseases -- References -- Part III: Evidence-Based PET in Cardiology -- 11: Evidence-Based PET for Cardiac Diseases -- 11.1 Introduction -- 11.2 Myocardial Blood Flow Perfusion -- 11.2.1 Performance of PET/CT in the Assessment of Myocardial Perfusion in Comparison to Other Myocardial Perfusion Imaging Modalities ---

4.5 Carcinoma of Unknown Origin and Incidental Findings -- References -- 5: Evidence-Based PET for Thoracic Tumours -- 5.1 Introduction -- 5.2 Evidence-Based Data on PET in Primary Lung Tumours -- 5.2.1 Characterization of Solitary Pulmonary Nodules (SPNs) -- 5.2.1.1 Single-Time-Point 18F-FDG PET or PET/CT -- 5.2.1.2 Dual-Time-Point (DTP) PET -- 5.2.1.3 18F-FLT PET for Evaluation of Pulmonary Lesions -- 5.2.2 NSCLC Staging -- 5.2.2.1 N Staging -- 5.2.2.2 M Staging -- 5.2.3 Restaging After Induction Therapy and Prediction of Treatment Response -- 5.2.4 Radiation Therapy Pretreatment Planning in NSCLC -- 5.2.5 Diagnosis of Lung Cancer Recurrence -- 5.2.6 Prognostic Evaluation in NSCLC -- 5.2.7 Management of SCLC -- 5.3 Evidence-Based Data on PET in Pleural Tumours -- 5.4 Evidence-Based Data on PET in Thymic Epithelial Tumours ---

11.2.2 Prognostic Value of Myocardial PET -- 11.3 Assessment of Myocardial Viability -- 11.4 Microvascular Disease -- 11.5 Cardiac Hybrid Imaging -- 11.6 Cardiac Amyloidosis -- References -- Part IV: Evidence-Based PET in Infection and Inflammation -- 12: Evidence-Based PET for Infectious and Inflammatory Diseases -- 12.1 Introduction -- 12.2 Fever of Unknown Origin (FUO) -- 12.3 Large Vessel Vasculitis (LVV) -- 12.4 Infectious Endocarditis and Cardiovascular Implantable Electronic Device Infections -- 12.5 Vascular Graft Infections -- 12.6 Sarcoidosis -- 12.7 Musculoskeletal Infections -- 12.8 Inflammatory Rheumatic Diseases -- 12.9 Inflammatory Bowel Diseases -- References -- Part V: Evidence-Based PET in Neurology -- 13: Evidence-Based PET for Neurological Diseases -- 13.1 Introduction -- 13.2 Evidence-Based PET in Neurodegenerative Dementia -- 13.3 Evidence-Based PET for Movement Disorders ---

13.4 Evidence-Based PET for Psychiatric Disorders.

5.5 Evidence-Based Data on PET in Esophageal Tumours -- 5.5.1 Staging -- 5.5.2 Restaging -- 5.5.3 Predictive and Prognostic Value -- References -- 6: Evidence-Based PET for Breast Cancer -- 6.1 Introduction -- 6.2 Staging -- 6.3 Restaging and Assessment of Response to Neoadjuvant Therapy -- 6.4 Prognostic Value -- 6.5 Incidental 18F-FDG Uptake -- 6.6 18F-FDG Positron Emission Mammography -- 6.7 PET/MRI -- 6.8 Other PET Tracers Beyond 18F-FDG -- References -- 7: Evidence-Based PET for Abdominal and Pelvic Tumours -- 7.1 Introduction -- 7.2 PET in Gastrointestinal Tumours -- 7.2.1 Colorectal Cancer -- 7.2.2 Gastric Cancer -- 7.2.3 Anal Cancer -- 7.2.4 Stromal Tumours (GIST) -- 7.2.5 Hepato-biliary Tumours -- 7.2.6 Liver Metastases -- 7.2.7 Pancreatic Cancer -- 7.3 PET in Gynaecological Tumours -- 7.3.1 Cervical Cancer -- 7.3.2 Endometrial Cancer -- 7.3.3 Ovarian Cancer -- 7.3.4 Peritoneal Carcinomatosis ---

7.3.5 PET/MRI -- 7.4 PET in Uro-genital Tumours -- 7.4.1 Prostate Cancer.

8.5.3 Impact of PET in Patients with Paraneoplastic Syndromes -- References -- 9: Evidence-Based PET for Haematological Tumours -- 9.1 Introduction -- 9.2 18F-FDG PET or PET/CT in Staging or Detection -- 9.2.1 Post-transplant Lymphoproliferative Disorder -- 9.2.2 Follicular Lymphoma -- 9.2.3 Marginal Zone Lymphoma of the Mucosa-Associated Lymphoid Tissue -- 9.2.4 Bone Marrow Involvement in Lymphoma -- 9.2.5 Natural Killer/T-Cell Lymphoma -- 9.2.6 Multiple Myeloma -- 9.3 18F-FDG PET or PET/CT in Treatment Response Evaluation (Interim and/or End of Therapy) -- 9.3.1 Post-transplant Lymphoproliferative Disorder -- 9.3.2 Hodgkin and Non-Hodgkin Lymphomas -- 9.4 18F-FDG PET or PET/CT in Prognosis/Outcome Evaluation -- 9.4.1 Hodgkin and Non-Hodgkin Lymphomas -- 9.4.2 Multiple Myeloma -- 9.5 Prognostic Role of Semi-quantitative PET Parameters ---

9.6 18F-FDG PET or PET/CT in Comparison with Magnetic Resonance Imaging -- 9.7 Conclusions -- References.

10: Evidence-Based PET for Endocrine Tumours and Disorders -- 10.1 Introduction -- 10.2 Adrenal Tumours and Paragangliomas -- 10.2.1 Characterization of Adrenal Masses -- 10.2.2 Paragangliomas -- 10.3 Neuroblastoma -- 10.4 Merkel Cell Carcinoma -- 10.5 Gastroenteropancreatic and Pulmonary Neuroendocrine Tumours -- 10.6 Congenital Hyperinsulinism -- 10.7 Thyroid Diseases -- 10.7.1 Thyroid Incidentalomas -- 10.7.2 Indeterminate Thyroid Nodules -- 10.7.3 Recurrence of Differentiated Thyroid Cancer -- 10.7.4 Recurrence of Medullary Thyroid Cancer -- 10.8 Parathyroid Diseases -- References -- Part III: Evidence-Based PET in Cardiology -- 11: Evidence-Based PET for Cardiac Diseases -- 11.1 Introduction -- 11.2 Myocardial Blood Flow Perfusion -- 11.2.1 Performance of PET/CT in the Assessment of Myocardial Perfusion in Comparison to Other Myocardial Perfusion Imaging Modalities ---

13.5 Conclusions -- References -- Part VI: Miscellaneous -- 14: Meta-Analyses on Technical Aspects of PET -- 14.1 Introduction -- 14.2 Factors Affecting 18F-FDG Uptake -- 14.3 Repeatability of the Quantitative Measurements -- 14.4 Dual-Time-Point Imaging -- 14.5 Correlation Between Proliferation Markers (Ki-67) and Tracer Uptake in Tumours -- 14.6 Correlation Between 18F-FDG SUVmax and ADC Values in Tumour Tissues -- 14.7 Diagnostic Performance of Hybrid Imaging in Oncology -- 14.8 Varia -- References.

4.5 Carcinoma of Unknown Origin and Incidental Findings -- References -- 5: Evidence-Based PET for Thoracic Tumours -- 5.1 Introduction -- 5.2 Evidence-Based Data on PET in Primary Lung Tumours -- 5.2.1 Characterization of Solitary Pulmonary Nodules (SPNs) -- 5.2.1.1 Single-Time-Point 18F-FDG PET or PET/CT -- 5.2.1.2 Dual-Time-Point (DTP) PET -- 5.2.1.3 18F-FLT PET for Evaluation of Pulmonary Lesions -- 5.2.2 NSCLC Staging -- 5.2.2.1 N Staging -- 5.2.2.2 M Staging -- 5.2.3 Restaging After Induction Therapy and Prediction of Treatment Response -- 5.2.4 Radiation Therapy Pretreatment Planning in NSCLC -- 5.2.5 Diagnosis of Lung Cancer Recurrence -- 5.2.6 Prognostic Evaluation in NSCLC -- 5.2.7 Management of SCLC -- 5.3 Evidence-Based Data on PET in Pleural Tumours -- 5.4 Evidence-Based Data on PET in Thymic Epithelial Tumours ---

7.4.1.1 Radiolabelled Choline PET for Prostate Cancer -- 7.4.1.2 Radiolabelled PSMA PET in Prostate Cancer -- 7.4.1.3 Fluciclovine PET in Prostate Cancer -- 7.4.1.4 Incidental 18F-FDG Uptake in the Prostate -- 7.4.2 Bladder Cancer -- 7.4.3 Renal Cell Carcinoma -- 7.4.4 Testicular and Penile Cancer -- References -- 8: Evidence-Based PET for Cutaneous, Musculoskeletal and Unknown Primary Tumours -- 8.1 Introduction -- 8.2 PET in Malignant Melanoma -- 8.2.1 Introduction -- 8.2.2 Staging -- 8.2.3 Restaging and Treatment Monitoring -- 8.3 PET in Sarcomas -- 8.3.1 Introduction -- 8.3.2 Staging -- 8.3.3 Restaging and Treatment Monitoring -- 8.4 PET for Bone Metastases -- 8.4.1 Introduction -- 8.4.2 Detection of Bone Metastases -- 8.5 PET for Cancer of Unknown Primary (CUP) and Paraneoplastic Syndromes -- 8.5.1 Introduction -- 8.5.2 Impact of PET in Patients with CUP ---

001894787

express

(Au-PeEL)EBL6363136

(MiAaPQ)EBC6363136

(OCoLC)1162841818